Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Rankin, E. D. Articles by Layne, R. D. Search for Related Content PubMed Citation Articles by Rankin, E. D. Articles by Layne, R. D. Alzheimer's Disease

The Use of Olanzapine in the Treatment of Negative Symptoms in Alzheimer’s Disease

Received May 8, 2003; revised May 19, 2004; accepted July 17, 2004. From the Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, West Virginia. Address correspondence to Dr. Rankin, Department of Behavioral Medicine and Psychiatry, West Virginia University, 930 Chestnut Ridge Rd., Morgantown, WV 26505-2854; erankin{at}hsc.wvu.edu (E-mail).

ABSTRACT

The authors report findings from an 8-week, open-label trial conducted to evaluate efficacy of olanzapine in treating negative symptoms in Alzheimer’s disease (AD). Subjects were AD patients age 50 and older who exhibited untreated neuropsychiatric symptoms. Findings suggest that a therapeutic profile for olanzapine may be appropriate for AD patients experiencing neuropsychiatric problems.

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us